New Releases from NCBI BookshelfEculizumab for treating relapsing neuromyelitis optica (terminated appraisal).Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal).
Post Content
Uncategorized
Uncategorized
New Releases from NCBI BookshelfAnti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis [Internet].Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis [Internet].
Diabetic retinopathy is a major cause of sight loss in people with diabetes. The most severe form, proliferative diabetic retinopathy,
Uncategorized
New Releases from NCBI BookshelfMeeting the needs of women in the perinatal period, who use or are in treatment for using drugs: A mixed-methods systematic review [Internet].Meeting the needs of women in the perinatal period, who use or are in treatment for using drugs: A mixed-methods systematic review [Internet].
Women who use and/or are in treatment for using drugs during the perinatal period have complex health and social care
Uncategorized
New Releases from NCBI BookshelfElafibranor (Iqirvo): Indication: For the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA: Reimbursement Recommendation [Internet].Elafibranor (Iqirvo): Indication: For the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Iqirvo be reimbursed by public drug plans for the treatment of primary biliary cholangitis
Uncategorized
New Releases from NCBI BookshelfPolatuzumab Vedotin (Polivy): Indication: Polivy (polatuzumab vedotin for injection) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T-cell/histiocyte rich LBCL that are classified as activated B-cell-like (ABC) lymphoma subtype: Reimbursement Recommendation [Internet].Polatuzumab Vedotin (Polivy): Indication: Polivy (polatuzumab vedotin for injection) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T-cell/histiocyte rich LBCL that are classified as activated B-cell-like (ABC) lymphoma subtype: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Polivy in combination with rituximab, cyclophosphamide, doxorubicin , and prednisone (R-CHP) should be reimbursed
Uncategorized
New Releases from NCBI BookshelfOlopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Ryaltris): Therapeutic area: Seasonal allergic rhinitis: Reimbursement Review [Internet].Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Ryaltris): Therapeutic area: Seasonal allergic rhinitis: Reimbursement Review [Internet].
Post Content
Uncategorized
New Releases from NCBI BookshelfFerric Carboxymaltose (Ferinject): Therapeutic area: Iron deficiency in adult patients with heart failure: Reimbursement Review [Internet].Ferric Carboxymaltose (Ferinject): Therapeutic area: Iron deficiency in adult patients with heart failure: Reimbursement Review [Internet].
Post Content
Uncategorized
New Releases from NCBI BookshelfTrastuzumab Deruxtecan (Enhertu): Therapeutic area: Gastric or gastroesophageal junction adenocarcinoma: Reimbursement Review [Internet].Trastuzumab Deruxtecan (Enhertu): Therapeutic area: Gastric or gastroesophageal junction adenocarcinoma: Reimbursement Review [Internet].
Post Content
